NCT06074562

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 405 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.

Conditions

• Diabetic Peripheral Neuropathy

Interventions

Type	Name	Description
DRUG	LY3556050	Administered orally.
DRUG	Placebo	Administered orally.

Timeline

• Start date: 2023-10-05
• Primary completion: 2025-06-11
• Completion: 2025-06-11
• First posted: 2023-10-10
• Last updated: 2025-07-03

Locations

70 sites across 5 countries: United States, Czechia, Japan, Poland, South Korea

Regulatory

• FDA-regulated drug study